Gagnon Securities LLC Raises Holdings in Johnson & Johnson (JNJ)

Gagnon Securities LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,543 shares of the company’s stock after purchasing an additional 129 shares during the quarter. Gagnon Securities LLC’s holdings in Johnson & Johnson were worth $715,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Vanguard Group Inc. lifted its position in shares of Johnson & Johnson by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 213,433,449 shares of the company’s stock valued at $29,490,100,000 after acquiring an additional 3,235,861 shares during the last quarter. Vanguard Group Inc lifted its position in shares of Johnson & Johnson by 1.5% during the 3rd quarter. Vanguard Group Inc now owns 213,433,449 shares of the company’s stock valued at $29,490,100,000 after acquiring an additional 3,235,861 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Johnson & Johnson by 1.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 33,892,560 shares of the company’s stock valued at $4,682,935,000 after acquiring an additional 435,564 shares during the last quarter. Morgan Stanley lifted its position in shares of Johnson & Johnson by 6.3% during the 3rd quarter. Morgan Stanley now owns 22,920,470 shares of the company’s stock valued at $3,166,921,000 after acquiring an additional 1,352,484 shares during the last quarter. Finally, Legal & General Group Plc lifted its position in shares of Johnson & Johnson by 1.4% during the 3rd quarter. Legal & General Group Plc now owns 12,824,479 shares of the company’s stock valued at $1,771,956,000 after acquiring an additional 173,991 shares during the last quarter. 67.32% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages have recently commented on JNJ. Credit Suisse Group increased their price objective on Johnson & Johnson from $151.00 to $152.00 and gave the company an “outperform” rating in a research report on Wednesday. Raymond James increased their price objective on Johnson & Johnson from $145.00 to $147.00 and gave the company an “outperform” rating in a research report on Wednesday. BMO Capital Markets increased their price objective on Johnson & Johnson from $154.00 to $157.00 and gave the company an “outperform” rating in a research report on Wednesday. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 price objective for the company in a research report on Wednesday, March 27th. Finally, Barclays reiterated an “equal weight” rating and set a $135.00 price objective (down previously from $137.00) on shares of Johnson & Johnson in a research report on Wednesday, January 23rd. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $146.40.

JNJ opened at $137.52 on Friday. The firm has a market capitalization of $368.95 billion, a PE ratio of 16.81, a price-to-earnings-growth ratio of 2.21 and a beta of 0.68. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.99. The company has a quick ratio of 1.20, a current ratio of 1.47 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.03 by $0.07. The company had revenue of $20.02 billion during the quarter, compared to analyst estimates of $19.55 billion. Johnson & Johnson had a return on equity of 35.63% and a net margin of 18.75%. The company’s revenue for the quarter was up .1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.06 earnings per share. Sell-side analysts anticipate that Johnson & Johnson will post 8.58 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Gagnon Securities LLC Raises Holdings in Johnson & Johnson (JNJ)” was originally reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.baseballdailydigest.com/news/2019/04/21/gagnon-securities-llc-raises-holdings-in-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: How do buyers and sellers choose a strike price?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.